

Parkinson's Disease Therapeutics Market Research Report by Type (Intestinal Infusion, Oral, Subcutaneous, and Transdermal), by Drug Class (Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor, Dopamine Receptor Agonist, and MAO Inhibitor), by Distribution Channel, by End Use - Global Forecast to 2025 - Cumulative Impact of COVID-19

<https://marketpublishers.com/r/P802EB92A923EN.html>

Date: February 2021

Pages: 187

Price: US\$ 3,949.00 (Single User License)

ID: P802EB92A923EN

Abstracts

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Parkinson's Disease Therapeutics Market is expected to grow from USD 5,301.27 Million in 2020 to USD 7,522.33 Million by the end of 2025.
2. The Global Parkinson's Disease Therapeutics Market is expected to grow from EUR 4,648.26 Million in 2020 to EUR 6,595.72 Million by the end of 2025.
3. The Global Parkinson's Disease Therapeutics Market is expected to grow from GBP 4,132.31 Million in 2020 to GBP 5,863.61 Million by the end of 2025.
4. The Global Parkinson's Disease Therapeutics Market is expected to grow from JPY 565,780.91 Million in 2020 to JPY 802,824.13 Million by the end of 2025.
5. The Global Parkinson's Disease Therapeutics Market is expected to grow from AUD 7,698.16 Million in 2020 to AUD 10,923.43 Million by the end of 2025.

Market Segmentation & Coverage:

This research report categorizes the Parkinson's Disease Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

'The Intestinal Infusion is projected to witness the highest growth during the forecast period'

Based on Type, the Parkinson's Disease Therapeutics Market studied across Intestinal Infusion, Oral, Subcutaneous, and Transdermal. The Oral commanded the largest size in the Parkinson's Disease Therapeutics Market in 2020. On the other hand, the Intestinal Infusion is expected to grow at the fastest CAGR during the forecast period.

'The Anticholinergic is projected to witness the highest growth during the forecast period'

Based on Drug Class, the Parkinson's Disease Therapeutics Market studied across Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor, Dopamine Receptor Agonist, and MAO Inhibitor. The Carbidopa/Levodopa commanded the largest size in the Parkinson's Disease Therapeutics Market in 2020. On the other hand, the Anticholinergic is expected to grow at the fastest CAGR during the forecast period.

'The Online Pharmacy is projected to witness the highest growth during the forecast period'

Based on Distribution Channel, the Parkinson's Disease Therapeutics Market studied across Hospital Pharmacy, Online Pharmacy, and Retailer Pharmacy. The Hospital Pharmacy commanded the largest size in the Parkinson's Disease Therapeutics Market in 2020. On the other hand, the Online Pharmacy is expected to grow at the fastest CAGR during the forecast period.

'The Clinic is projected to witness the highest growth during the forecast period'

Based on End Use, the Parkinson's Disease Therapeutics Market studied across Clinic and Hospital. The Hospital commanded the largest size in the Parkinson's Disease Therapeutics Market in 2020. On the other hand, the Clinic is expected to grow at the fastest CAGR during the forecast period.

'The Asia-Pacific is projected to witness the highest growth during the forecast period'

Based on Geography, the Parkinson's Disease Therapeutics Market studied across

Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded the largest size in the Parkinson's Disease Therapeutics Market in 2020. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Parkinson's Disease Therapeutics Market including Abbvie, Inc., ACADIA Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., Apotex, Inc., Bausch Health Companies, Inc., Boehringer Ingelheim International GmbH, Cipla, Inc., Daiichi Sankyo Company, H. Lundbeck A/S, Mylan N.V., Novartis AG, Orion Corporation, Par Pharmaceutical by Endo International PLC, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., and WOCKHARDT.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so far and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

360iResearch FPNV Positioning Matrix:

The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Parkinson's Disease Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

360iResearch Competitive Strategic Window:

The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:

1. **Market Penetration:** Provides comprehensive information on the market offered by the key players
2. **Market Development:** Provides in-depth information about lucrative emerging markets and analyzes the markets
3. **Market Diversification:** Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. **Competitive Assessment & Intelligence:** Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. **Product Development & Innovation:** Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Parkinson's Disease Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Parkinson's Disease Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Parkinson's Disease Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Parkinson's Disease Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Parkinson's Disease Therapeutics Market?
6. What are the modes and strategic moves considered suitable for entering the Global Parkinson's Disease Therapeutics Market?

Contents

1. PREFACE

- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Stakeholders

2. RESEARCH METHODOLOGY

- 2.1. Research Process
 - 2.1.1. Define: Research Objective
 - 2.1.2. Determine: Research Design
 - 2.1.3. Prepare: Research Instrument
 - 2.1.4. Collect: Data Source
 - 2.1.5. Analyze: Data Interpretation
 - 2.1.6. Formulate: Data Verification
 - 2.1.7. Publish: Research Report
 - 2.1.8. Repeat: Report Update
- 2.2. Research Execution
 - 2.2.1. Initiation: Research Process
 - 2.2.2. Planning: Develop Research Plan
 - 2.2.3. Execution: Conduct Research
 - 2.2.4. Verification: Finding & Analysis
 - 2.2.5. Publication: Research Report
- 2.3. Research Outcome

3. EXECUTIVE SUMMARY

- 3.1. Introduction
- 3.2. Market Outlook
- 3.3. Type Outlook
- 3.4. Drug Class Outlook
- 3.5. Distribution Channel Outlook
- 3.6. End Use Outlook

- 3.7. Geography Outlook
- 3.8. Competitor Outlook

4. MARKET OVERVIEW

- 4.1. Introduction
- 4.2. Cumulative Impact of COVID-19

5. MARKET INSIGHTS

5.1. Market Dynamics

5.1.1. Drivers

5.1.1.1. Growing aging population and the associated Increase in the prevalence of Parkinson's disease

5.1.1.2. Development of new therapies and minimally invasive new devices

5.1.2. Restraints

5.1.2.1. Availability of alternative treatments

5.1.3. Opportunities

5.1.3.1. Increasing pace of R&D by the government in the U.S., the UK, and other countries for Parkinson's disease management

5.1.3.2. Strong drug pipeline under clinical research

5.1.3.3. Potential for pharmaceutical companies due to patent expiry

5.1.4. Challenges

5.1.4.1. Sales erosion due to expiry of patents

5.2. Porters Five Forces Analysis

5.2.1. Threat of New Entrants

5.2.2. Threat of Substitutes

5.2.3. Bargaining Power of Customers

5.2.4. Bargaining Power of Suppliers

5.2.5. Industry Rivalry

6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, BY TYPE

- 6.1. Introduction
- 6.2. Intestinal Infusion
- 6.3. Oral
- 6.4. Subcutaneous
- 6.5. Transdermal

7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, BY DRUG CLASS

- 7.1. Introduction
- 7.2. Anticholinergic
- 7.3. Carbidopa/Levodopa
- 7.4. COMT Inhibitor
- 7.5. Dopamine Receptor Agonist
- 7.6. MAO Inhibitor

8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

- 8.1. Introduction
- 8.2. Hospital Pharmacy
- 8.3. Online Pharmacy
- 8.4. Retailer Pharmacy

9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET, BY END USE

- 9.1. Introduction
- 9.2. Clinic
- 9.3. Hospital

10. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET

- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States

11. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET

- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia

- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. South Korea
- 11.10. Thailand

12. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET

- 12.1. Introduction
- 12.2. France
- 12.3. Germany
- 12.4. Italy
- 12.5. Netherlands
- 12.6. Qatar
- 12.7. Russia
- 12.8. Saudi Arabia
- 12.9. South Africa
- 12.10. Spain
- 12.11. United Arab Emirates
- 12.12. United Kingdom

13. COMPETITIVE LANDSCAPE

- 13.1. FPNV Positioning Matrix
 - 13.1.1. Quadrants
 - 13.1.2. Business Strategy
 - 13.1.3. Product Satisfaction
- 13.2. Market Ranking Analysis
- 13.3. Market Share Analysis
- 13.4. Competitor SWOT Analysis
- 13.5. Competitive Scenario
 - 13.5.1. Merger & Acquisition
 - 13.5.2. Agreement, Collaboration, & Partnership
 - 13.5.3. New Product Launch & Enhancement
 - 13.5.4. Investment & Funding
 - 13.5.5. Award, Recognition, & Expansion

14. COMPANY USABILITY PROFILES

- 14.1. Abbvie, Inc.
- 14.2. ACADIA Pharmaceuticals, Inc.
- 14.3. Amneal Pharmaceuticals, Inc.
- 14.4. Apotex, Inc.
- 14.5. Bausch Health Companies, Inc.
- 14.6. Boehringer Ingelheim International GmbH
- 14.7. Cipla, Inc.
- 14.8. Daiichi Sankyo Company
- 14.9. H. Lundbeck A/S
- 14.10. Mylan N.V.
- 14.11. Novartis AG
- 14.12. Orion Corporation
- 14.13. Par Pharmaceutical by Endo International PLC
- 14.14. Sun Pharmaceutical Industries Limited
- 14.15. Teva Pharmaceutical Industries Ltd.
- 14.16. UCB S.A.
- 14.17. WOCKHARDT

15. APPENDIX

- 15.1. Discussion Guide
- 15.2. License & Pricing

List Of Tables

LIST OF TABLES

TABLE 1. CURRENCY CONVERSION RATES

TABLE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INTESTINAL INFUSION, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGIC, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CARBIDOPA/LEVODOPA, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITOR, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR AGONIST, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO INHIBITOR, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD

MILLION)

TABLE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAILER PHARMACY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINIC, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 21. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 22. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 23. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 24. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 25. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 26. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 27. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 28. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 29. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 30. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 31. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 32. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 33. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 34. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 35. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 36. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 37. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 38. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 39. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 40. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 41. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 42. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 43. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 44. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 45. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 46. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 47. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 48. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 49. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 50. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 51. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 52. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 53. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 54. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE,

BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 55. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 56. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 57. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 58. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 59. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 60. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 61. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 62. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 63. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 64. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 65. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 66. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 67. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 68. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 69. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 70. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 71. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 72. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 73. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 74. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 75. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 76. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 77. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 78. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 79. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 80. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 81. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 82. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 83. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 84. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 85. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 86. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 87. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 88. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 89. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 90. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 91. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025

(USD/EUR/GBP/JPY/AUD MILLION)

TABLE 92. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 93. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 94. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 95. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 96. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 97. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 98. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 99. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 100. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 101. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 102. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 103. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 104. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 105. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 106. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 107. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 108. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 109. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 110. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY

DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 111. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 112. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 113. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 114. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 115. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 116. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 117. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 118. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 119. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 120. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 121. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 122. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 123. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 124. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 125. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 126. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 127. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 128. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 129. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 130. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 131. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 132. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 133. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 134. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 135. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 136. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 137. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: SCORES

TABLE 138. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: BUSINESS STRATEGY

TABLE 139. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: PRODUCT SATISFACTION

TABLE 140. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: RANKING

TABLE 141. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: MERGER & ACQUISITION

TABLE 142. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP

TABLE 143. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT

TABLE 144. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: INVESTMENT & FUNDING

TABLE 145. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION

TABLE 146. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: LICENSE & PRICING

List Of Figures

LIST OF FIGURES

- FIGURE 1. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: RESEARCH PROCESS
- FIGURE 2. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: RESEARCH EXECUTION
- FIGURE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2020 VS 2025 (USD MILLION)
- FIGURE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2020 (USD MILLION)
- FIGURE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
- FIGURE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 (USD MILLION)
- FIGURE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2020 (USD MILLION)
- FIGURE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
- FIGURE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2025 (USD MILLION)
- FIGURE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
- FIGURE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
- FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
- FIGURE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: MARKET DYNAMICS
- FIGURE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
- FIGURE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2020 VS 2025 (%)
- FIGURE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2020 VS 2025 (USD MILLION)
- FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2025
- FIGURE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY

INTESTINAL INFUSION, 2020 VS 2025 (USD MILLION)

FIGURE 19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2020 VS 2025 (USD MILLION)

FIGURE 20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, 2020 VS 2025 (USD MILLION)

FIGURE 21. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, 2020 VS 2025 (USD MILLION)

FIGURE 22. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (%)

FIGURE 23. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (USD MILLION)

FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025

FIGURE 25. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGIC, 2020 VS 2025 (USD MILLION)

FIGURE 26. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CARBIDOPA/LEVODOPA, 2020 VS 2025 (USD MILLION)

FIGURE 27. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITOR, 2020 VS 2025 (USD MILLION)

FIGURE 28. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR AGONIST, 2020 VS 2025 (USD MILLION)

FIGURE 29. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO INHIBITOR, 2020 VS 2025 (USD MILLION)

FIGURE 30. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2025 (%)

FIGURE 31. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2020 VS 2025 (USD MILLION)

FIGURE 32. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025

FIGURE 33. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2020 VS 2025 (USD MILLION)

FIGURE 34. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, 2020 VS 2025 (USD MILLION)

FIGURE 35. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAILER PHARMACY, 2020 VS 2025 (USD MILLION)

FIGURE 36. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2020 VS 2025 (%)

FIGURE 37. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2020 VS 2025 (USD MILLION)

FIGURE 38. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2025

FIGURE 39. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINIC, 2020 VS 2025 (USD MILLION)

FIGURE 40. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL, 2020 VS 2025 (USD MILLION)

FIGURE 41. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)

FIGURE 42. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)

FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025

FIGURE 44. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 45. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 46. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 47. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 48. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 49. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)

FIGURE 50. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)

FIGURE 51. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025

FIGURE 52. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 53. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 54. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 55. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 56. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 57. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE,

BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 58. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 59. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 60. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 61. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)

FIGURE 62. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)

FIGURE 63. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025

FIGURE 64. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 65. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 66. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 67. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 68. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 69. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 70. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 71. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 72. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 73. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 74. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 75. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET: 360RESEARCH FPNV POSITIONING MATRIX

FIGURE 76. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET:

360IRESEARCH MARKET SHARE ANALYSIS

FIGURE 77. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET:
COMPETITOR SWOT ANALYSIS

FIGURE 78. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PARKINSON'S
DISEASE THERAPEUTICS MARKET, BY TYPE

I would like to order

Product name: Parkinson's Disease Therapeutics Market Research Report by Type (Intestinal Infusion, Oral, Subcutaneous, and Transdermal), by Drug Class (Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor, Dopamine Receptor Agonist, and MAO Inhibitor), by Distribution Channel, by End Use - Global Forecast to 2025 - Cumulative Impact of COVID-19

Product link: <https://marketpublishers.com/r/P802EB92A923EN.html>

Price: US\$ 3,949.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P802EB92A923EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970